Reported a net loss of $7.5 million for the three months ended March 31, 2026, compared to $6.7 million in the same period of 2025. Research and development expenses increased to $5.2 million from $4.6 million in Q1 2025, driven by clinical development of TBS-2025 and increased personnel costs. Cash and cash equivalents stood at $6.3 million as of March 31, 2026. Entered into a $50 million revolving credit facility with Parkview Holdings One LLC in April 2026 to fund operations through the end of 2028. Maintained a single reportable segment focused on advancing immuno-oncology therapies.